The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrom, (PMP-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.
1. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of:
(a) amino acids 32-965 of SEQ ID NO: 2;
(b) SEQ ID NO: 2;
(c) amino acids 625-700 of SEQ ID NO: 2;
(d) amino acids 590-625 of SEQ ID NO: 2;
(e) amino acids 1-500 of SEQ ID NO: 2;
(f) the amino acid sequence encoded by the Chlamydia insert in Escherichia coli M15 assigned as ATCC PTA No. 2462; and
(g) a combination of two or more amino acid sequences of (a)-(f).
2. The polypeptide of claim 1 , further comprising a heterologous polypeptide.
3. The polypeptide of claim 2 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
4. The polypeptide of claim 2 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 4; and an amino acid sequence encoded by a Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.
5. A composition comprising the polypeptide of claim 1 and a carrier.
6. The composition of claim 5 , further comprising an adjuvant.
7. The composition of claim 5 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of two or more of said immunogens.
8. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or the amino acid sequence encoded by a Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.
9. The polypeptide of claim 8 , further comprising a heterologous polypeptide.
10. The polypeptide of claim 9 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
11. The polypeptide of claim 9 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 2; amino acids 32-965 of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and an amino acid sequence encoded by a Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.
12. A composition comprising the polypeptide of claim 8 and a carrier.
13. The composition of claim 12 , further comprising an adjuvant.
14. The composition of claim 12 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of one or more of said immunogens.
15. An isolated polypeptide consisting of the amino acid sequence selected from the group consisting of: amino acids 32-965 of SEQ ID NO: 2; SEQ ID NO: 2; the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; and amino acids 1-500 of SEQ ID NO: 2.
16. A composition comprising the polypeptide of claim 15 and a carrier.
17. The composition of claim 16 , further comprising an adjuvant.
18. The composition of claim 16 , further comprising a heterologous polypeptide.
19. The composition of claim 18 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
20. The composition of claim 18 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 34; and an amino acid sequence encoded by a Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.
21. The composition of claim 16 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of two or more of said immunogens.
22. An isolated polypeptide consisting of the amino acid sequence selected from the group consisting of: SEQ ID NO: 4, amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; and amino acids 1-500 of SEQ ID NO: 4.
23. A composition comprising the polypeptide of claim 22 and a carrier.
24. The composition of claim 23 , further comprising an adjuvant.
25. The composition of claim 23 , further comprising a heterologous polypeptide.
26. The composition of claim 25 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
27. The composition of claim 25 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 2; amino acids 32-965 of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and an amino acid sequence encoded by a Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.
28. The composition of claim 23 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of two or more of said immunogens.
29. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of: amino acids 32-965 of SEQ ID NO: 2; SEQ ID NO: 2; the amino acid sequence encoded by the Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; and amino acids 1-500 of SEQ ID NO: 2, wherein said isolated polypeptide further comprises a heterologous polypeptide.
30. The polypeptide of claim 29 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
31. The polypeptide of claim 29 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 4; amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; amino acids 1-500 of SEQ ID NO: 34; and an amino acid sequence encoded by a Chlamydia insert in E. coli TOP10 assigned as ATCC PTA No. 2461.
32. A composition comprising the polypeptide of claim 29 and a carrier.
33. The composition of claim 32 , further comprising an adjuvant.
34. The composition of claim 32 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of two or more of said immunogens.
35. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 4, amino acids 13-40 of SEQ ID NO: 4; amino acids 70-110 of SEQ ID NO: 4; amino acids 150-225 of SEQ ID NO: 4; amino acids 250-290 of SEQ ID NO: 4; amino acids 370-455 of SEQ ID NO: 4; amino acids 400-455 of SEQ ID NO: 4; amino acids 470-520 of SEQ ID NO: 4; amino acids 615-670 of SEQ ID NO: 4; amino acids 710-775 of SEQ ID NO: 4; amino acids 765-825 of SEQ ID NO: 4; amino acids 830-860 of SEQ ID NO: 4; and amino acids 1-500 of SEQ ID NO: 4, wherein said isolated polypeptide further comprises a heterologous polypeptide.
36. The polypeptide of claim 35 , wherein said heterologous polypeptide is selected from the group consisting of a pre- and/or pro-sequence, an affinity purification sequence, and an immunogenic sequence.
37. The polypeptide of claim 35 , wherein said heterologous polypeptide is selected from the group consisting of SEQ ID NO: 2; amino acids 32-965 of SEQ ID NO: 2; amino acids 15-56 of SEQ ID NO: 2; amino acids 15-121 of SEQ ID NO: 2; amino acids 45-125 of SEQ ID NO: 2; amino acids 125-190 of SEQ ID NO: 2; amino acids 195-261 of SEQ ID NO: 2; amino acids 275-366 of SEQ ID NO: 2; amino acids 375-440 of SEQ ID NO: 2; amino acids 440-490 of SEQ ID NO: 2; amino acids 525-590 of SEQ ID NO: 2; amino acids 590-625 of SEQ ID NO: 2; amino acids 615-650 of SEQ ID NO: 2; amino acids 625-700 of SEQ ID NO: 2; amino acids 725-800 of SEQ ID NO: 2; amino acids 755-775 of SEQ ID NO: 2; amino acids 785-845 of SEQ ID NO: 2; amino acids 815-865 of SEQ ID NO: 2; amino acids 1-31 of SEQ ID NO: 2; amino acids 1-500 of SEQ ID NO: 2; and an amino acid sequence encoded by a Chlamydia insert in E. coli M15 assigned as ATCC PTA No. 2462.
38. A composition comprising the polypeptide of claim 35 and a carrier.
39. The composition of claim 38 , further comprising an adjuvant.
40. The composition of claim 38 , further comprising an immunogen selected from the group consisting of a lipid, a lipoprotein, a phospholipid, a lipooligosaccharide, a protein, an attenuated or inactivated organism, and a combination of two or more of said immunogens.